Cao Wei, Liu Jian-Hua, Zhang Hong, Zhang Lei, Zhang Li-Yuan, Pan Ming-Ming
Nephrology Department, The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
Zhongguo Zhen Jiu. 2010 Nov;30(11):891-5.
To compare the effect on erythropoietin (Epo) resistance between acupoint injection and subcutaneous injection of rHuEpo in patients with chronic renal failure (CRF).
Thirty-eight cases were randomly divided into two groups, 19 cases in each one. In subcutaneous injection group (control group), subcutaneous injection of rHuEpo was administered, 3 times a week, lasting 2 months. In acupoint group (observation group), rHuEpo was injected on unilateral Shenshu (BL 23) and Zusanli (ST 36), one point was chosen each time, the bilateral acupoints were injected alternatively, 3 times a week, for 2 months. Meanwhile, a normal control group of 19 healthy persons was set up. The levels of CRP, IL-6, TNF-alpha, Scr, BUN, Hb, Hct and SF were observed.
Before treatment, the values of CRP, IL-6 and TNF-alpha in two groups were all higher than those in normal control group (all P < 0.01). After treatment for 2 months, the values of CRP, IL-6,TNF-alpha, Scr and BUN in two groups decreased apparently and those of Hb, Hct and SF increased obviously, indicating statistic significant differences as compared with the values before treatment separately (P < 0.05, P < 0.01). In comparison between two groups after treatment, every index above in observation group was improved much significantly (P < 0.05, P < 0.01).
Acupoint injection of rHuEpo at Zusanli (ST 36) and Shenshu (BL 23) increases significantly the values of Hb, Hct and SF, and decreases apparently the values of BUN, Scr and inflammatory factors, such as CRP, IL-6 and TNF-alpha as compared with subcutaneous injection. Acupoint injection improves Epo resistance and enhances Epo efficacy via alleviating micro-inflammatory state of the body.
比较穴位注射与皮下注射重组人促红细胞生成素（rHuEpo）对慢性肾衰竭（CRF）患者促红细胞生成素抵抗的影响。
将38例患者随机分为两组，每组19例。皮下注射组（对照组）皮下注射rHuEpo，每周3次，持续2个月。穴位组（观察组）于单侧肾俞穴（BL 23）和足三里穴（ST 36）注射rHuEpo，每次选1个穴位，双侧穴位交替注射，每周3次，共2个月。同时，设立19名健康人的正常对照组。观察CRP、IL-6、TNF-α、Scr、BUN、Hb、Hct及SF水平。
治疗前，两组CRP、IL-6及TNF-α值均高于正常对照组（均P<0.01）。治疗2个月后，两组CRP、IL-6、TNF-α、Scr及BUN值明显下降，Hb、Hct及SF值明显升高，与治疗前相比差异均有统计学意义（P<0.05，P<0.01）。治疗后两组比较，观察组上述各项指标改善更显著（P<0.05，P<0.01）。
与皮下注射相比，在足三里穴（ST 36）和肾俞穴（BL 23）穴位注射rHuEpo可显著提高Hb、Hct及SF值，明显降低BUN、Scr及CRP、IL-6、TNF-α等炎症因子值。穴位注射通过减轻机体微炎症状态改善促红细胞生成素抵抗，增强促红细胞生成素疗效。
